Hebei Senlang Biotechnology Inc., Ltd.
Clinical trials sponsored by Hebei Senlang Biotechnology Inc., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on tough T-Cell cancers in new trial Results expected Sep 2026 (estimated)
- Could CAR-T cells tame severe colitis? early trial launches Results expected Feb 2027 (estimated)
- New CAR-T therapy aims to tackle tough childhood leukemia Results expected Mar 2027 (estimated)
- Immune system reset: CAR T-Cells take on autoimmune diseases Results expected Aug 2027 (estimated)
-
New CAR t therapy aims to tackle tough multiple myeloma
Disease control Not yet recruitingThis early-stage trial is testing a new treatment called SENL103 for people with multiple myeloma that has returned or not responded to standard treatments. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The study will enroll 24 parti…
Phase 1/2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Not yet recruitingThis study tests a new treatment called S101 CAR-T cells for people with a type of T-cell cancer (T-LBL/ALL) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. Th…
Phase 2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control Not yet recruitingThis study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …
Phase 1/2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC